Invention Grant
- Patent Title: Sustained release olanzapine formulations
-
Application No.: US15926076Application Date: 2018-03-20
-
Publication No.: US10646443B2Publication Date: 2020-05-12
- Inventor: Carine Claassen-Punt , Mark Alan Smith , Ling Chen , Ari Andrew Gershon
- Applicant: Teva Pharmaceuticals International GMBH
- Applicant Address: CH Jona
- Assignee: Teva Pharmaceuticals International GmbH
- Current Assignee: Teva Pharmaceuticals International GmbH
- Current Assignee Address: CH Jona
- Agency: BakerHostetler
- Main IPC: A61K31/551
- IPC: A61K31/551 ; A61P25/18 ; A61K47/34 ; A61K9/14 ; A61K31/5513 ; A61K9/00 ; A61K9/16
Abstract:
The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.
Public/Granted literature
- US20180263911A1 Sustained Release Olanzapine Formulations Public/Granted day:2018-09-20
Information query
